Cyclic urea nucleosides. Cytidine deaminase activity as a function of aglycon ring size
作者:Paul S. Liu、Victor E. Marquez、John S. Driscoll、Richard W. Fuller、John J. McCormack
DOI:10.1021/jm00138a003
日期:1981.6
by the mercury-catalyzed condensation procedure. CDA activity varies significantly with the ring size of the urea aglycon the reaches its maximum level for the seven-membered analogues 16 and 17. The unexpected high potency of nucleoside 17 (Ki = 2.5 X 10(-8) M, human liver enzyme) is reported. This compound represents the most potent inhibitor of human liver CDA yet discovered.
合成了五种β-D-呋喃呋喃糖基环状脲核苷(14-18),其环大小为五至八元,并被评估为胞苷脱氨酶(CDA)抑制剂。在含有仅提供β-端基异构体的HgO / HgBr2混合物的比催化活性下,通过缩合反应利用前体保护的核苷(9-13),该缩合反应是利用硅烷化的脲与卤代糖。已知的1-(2,3,5-三-O-苯甲酰基-β-呋喃呋喃糖基)-1,2-二氢嘧啶-2-酮(19)的催化加氢提供与通过汞催化的缩合步骤获得的核苷10相同。CDA活性随尿素糖苷配基的环大小变化而显着变化,达到七元类似物16和17的最大水平。核苷17的意想不到的高效能(Ki = 2.5 X 10(-8)M,人肝酶)的报道。该化合物代表尚未发现的最有效的人类肝脏CDA抑制剂。